Comparative clinical effectiveness and value of novel interferon-free combination therapy for hepatitis C genotype 1 summary of California technology assessment forum report

JAMA Internal Medicine

Volumn 175, Issue 9, 2015, Pages 1559-1560

  Tice, Jeffrey A ^a   Chahal, Harinder S ^b   Ollendorf, Daniel A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; DASABUVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; INTERFERON;

BUDGET; CHRONIC HEPATITIS C; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT RESPONSE; COMPARATIVE STUDY; DRUG COMBINATION; ECONOMICS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; TREATMENT OUTCOME; UNITED STATES;

ANTIVIRAL AGENTS; CALIFORNIA; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; TREATMENT OUTCOME;

EID: 84941236428     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.3348     Document Type: Short Survey

References (12)

1. Tice JA, Ollendorf DA, Chahal HS, et al. The comparative clinical effectiveness and value of novel combination therapies for the treatment of patients with genotype 1 chronic hepatitis C infection: a technology assessment: final report. Boston, MA: Institute for Clinical and Economic Review; 2015. http://ctaf.org/sites/default/files/assessments/CTAF-HCV2-Final-Report-013015.pdf. Accessed February 2, 2015.
2. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859-1861.
3. National Hepatitis C Program Office, US Department of Veterans Affairs. Interferon and ribavirin treatment side effects. http://www.hepatitis.va.gov/provider/reviews/treatment-side-effects.asp. Accessed January 8, 2014.
4. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9(11):923-930.
5. US Food and Drug Administration. Guidance for industry: expedited programs for serious conditions-drugs and biologics. 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf. Accessed April 3, 2014.
6. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162(6):407-419.
7. California Department of Health Care Services. 6-month ACA Expansion Capitation Rate Summary-with SB78: January 1, 2014 - June 30, 2014. http://www.dhcs.ca.gov/dataandstats/reports/Documents/MMCD-Fin-Rpts/Medicaid-ACA-Expansion-Rates.pdf. Accessed November 12, 2014.
8. Grebely J, Pham ST, Matthews GV, et al; ATAHC Study Group. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2012;55(4):1058-1069.
9. Sacks-Davis R, Aitken CK, Higgs P, et al. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One. 2013;8(11):e80216.
10. Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49-57.
11. Talsma J. PBMs, insurers strike deals for Hep C drugs. Drug Topics. February 11, 2015. http://drugtopics.modernmedicine.com/drug-topics/news/pbms-insurers-strike-deals-hep-c-drugs. Accessed February 11, 2015.
12. Rockoff JD, Stynes T. Gilead Sciences down on discounting news. Wall Street Journal. February 4, 2015. http://www.wsj.com/articles/gilead-sciences-down-on-discounting-news-1423070093. Accessed March 31, 2015.